Associate Professor of Pediatrics
550 16th Street, 4th floor
San Francisco, CA 94143
Phone: (415) 476-4764
Fax: (415) 502-4372
- Swarthmore College, Swarthmore, PA, BA, chemistry and psychobiology, 1992-96
- School of Medicine, University of California, San Francisco, MD, 1996-2000
- School of Medicine, University of California, San Francisco, internship, pediatrics, 2000-01
- School of Medicine, University of California, San Francisco, residency, pediatrics, 2001-03
- Dana-Farber Cancer Institute and Children’s Hospital, Boston, MA, fellowship, pediatric hematology/oncology, 2004-07
- Harvard School of Public Health, MS, epidemiology
- American Board of Pediatrics, Hematology-Oncology
- Pediatric and young adult sarcoma
- Pediatric solid tumors
- New agents for pediatric cancer
UCSF Program Affiliations
Dr. Steven DuBois is a pediatric cancer specialist in the Children's Cancer and Blood Disease Program at UCSF Benioff Children's Hospital. He specializes in the treatment of solid cancers, such as neuroblastoma and Ewing sarcoma, in children and young adults.
DuBois earned a medical degree at the University of California, San Francisco and completed a pediatrics residency at UCSF. He completed a fellowship in pediatric hematology and oncology at the Dana-Farber Cancer Institute and Children's Hospital in Boston. He is a member of the Connective Tissue Oncology Society, the American Society of Pediatric Hematology/Oncology, and the American Society of Clinical Oncology.
Dr. DuBois’s research program is focused on developmental therapeutics for pediatric solid tumors, with an emphasis on neuroblastoma and Ewing sarcoma. Dr. DuBois has developed expertise in the use of 131I-MIBG as a targeted radiopharmaceutical for children with advanced neuroblastoma. He has published the most comprehensive evaluation of the hematologic toxicity of 131I-MIBG therapy in children with neuroblastoma. He has also established productive collaborations with laboratory scientists focused on the translational radiobiology of 131I-MIBG therapy for neuroblastoma. He has served as the study chair of two phase I clinical trials combining 131I-MIBG with two different radiation sensitizers: irinotecan and vorinostat.